<?xml version='1.0' encoding='utf-8'?>
<document id="19127490"><sentence text="Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause."><entity charOffset="0-14" id="DDI-PubMed.19127490.s1.e0" text="Desvenlafaxine" /><entity charOffset="18-27" id="DDI-PubMed.19127490.s1.e1" text="serotonin" /><entity charOffset="28-42" id="DDI-PubMed.19127490.s1.e2" text="norepinephrine" /><pair ddi="false" e1="DDI-PubMed.19127490.s1.e0" e2="DDI-PubMed.19127490.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19127490.s1.e0" e2="DDI-PubMed.19127490.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19127490.s1.e0" e2="DDI-PubMed.19127490.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19127490.s1.e1" e2="DDI-PubMed.19127490.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19127490.s1.e1" e2="DDI-PubMed.19127490.s1.e2" /></sentence><sentence text="Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Wyeth, is a novel salt form of the isolated major active metabolite of the antidepressant venlafaxine"><entity charOffset="0-14" id="DDI-PubMed.19127490.s2.e0" text="Desvenlafaxine" /><entity charOffset="18-27" id="DDI-PubMed.19127490.s2.e1" text="serotonin" /><entity charOffset="28-42" id="DDI-PubMed.19127490.s2.e2" text="norepinephrine" /><entity charOffset="172-183" id="DDI-PubMed.19127490.s2.e3" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e0" e2="DDI-PubMed.19127490.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e0" e2="DDI-PubMed.19127490.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e0" e2="DDI-PubMed.19127490.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e0" e2="DDI-PubMed.19127490.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e1" e2="DDI-PubMed.19127490.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e1" e2="DDI-PubMed.19127490.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e1" e2="DDI-PubMed.19127490.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e2" e2="DDI-PubMed.19127490.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19127490.s2.e2" e2="DDI-PubMed.19127490.s2.e3" /></sentence><sentence text=" Desvenlafaxine was developed as a slow-release tablet formulation and rapidly penetrates the brain upon administration supporting its direct effects on neuronal systems of the brain"><entity charOffset="1-15" id="DDI-PubMed.19127490.s3.e0" text="Desvenlafaxine" /></sentence><sentence text=" Unlike various other antidepressants including venlafaxine, desvenlafaxine is not metabolized by cytochrome p450 (CYP) enzyme pathways and is associated with minimal inhibition of CYP enzymes"><entity charOffset="48-59" id="DDI-PubMed.19127490.s4.e0" text="venlafaxine" /><entity charOffset="61-75" id="DDI-PubMed.19127490.s4.e1" text="desvenlafaxine" /><pair ddi="false" e1="DDI-PubMed.19127490.s4.e0" e2="DDI-PubMed.19127490.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19127490.s4.e0" e2="DDI-PubMed.19127490.s4.e1" /></sentence><sentence text=" This feature results in a comparatively low risk of drug-drug interaction and consistent intra-individual and inter-individual pharmacokinetic profiles" /><sentence text=" Desvenlafaxine has been recently approved by the US FDA for the treatment of major depressive disorder (MDD) based on a series of randomized, double-blind, placebo-controlled clinical trials indicating efficacy and safety for patients with MDD"><entity charOffset="1-15" id="DDI-PubMed.19127490.s6.e0" text="Desvenlafaxine" /></sentence><sentence text=" Studies have also supported the potential utility of desvenlafaxine in the treatment of vasomotor symptoms of menopause, anxiety symptoms and painful physical symptoms"><entity charOffset="54-68" id="DDI-PubMed.19127490.s7.e0" text="desvenlafaxine" /></sentence><sentence text=" However, concerns including mixed efficacy and adverse events need to be further explored in future studies" /><sentence text="" /></document>